Diagnoplex

About:

Diagnoplex develops non-invasive colorectal cancer screening tests and diagnostics.

Top Investors: Novartis Venture Fund, Debiopharm Innovation Fund, Neomed Management, Foundation for Innovation and Technology (FIT), Initiative Capital Romandie

Description:

Diagnoplex has been founded in 2005 supported by seed financing fron the Novartis Forschungsstiftung, Swiss Confederation CTI project, Canton de Vaud FIT and the Gebert RÃ¼f Stiftung. The company has performed a 140 patient prospective pilot study demonstrating technical and clinical feasibility of its colorectal cancer screening test COLOX as well as its high sensitivity and specificity.

Total Funding Amount:

$9.85M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Lausanne, Vaud, Switzerland

Founded Date:

2005-01-01

Contact Email:

info(AT)diagnoplex.com

Founders:

Stavros Therianos

Number of Employees:

1-10

Last Funding Date:

2013-06-07

IPO Status:

Private

Industries: